Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 39% Improvement Relative Risk c19early.org/mf Ando et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 28,093 patients in the USA (January - November 2020) Lower hospitalization with metformin (p=0.044) Ando et al., Scientific Reports, doi:10.1038/s41598-021-96720-x Favors metformin Favors control
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States
Ando et al., Scientific Reports, doi:10.1038/s41598-021-96720-x
Ando et al., Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United.., Scientific Reports, doi:10.1038/s41598-021-96720-x
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 28,093 COVID+ patients in the USA, showing lower risk of hospitalization with metformin use.
risk of hospitalization, 39.0% lower, HR 0.61, p = 0.04, treatment 19 of 663 (2.9%), control 1,056 of 27,430 (3.8%), adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ando et al., 9 Sep 2021, retrospective, USA, peer-reviewed, 6 authors, study period 1 January, 2020 - 30 November, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: www.nature.com/scientificreports OPEN Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States Wataru Ando1,5*, Takeshi Horii2,5, Takayuki Uematsu3, Hideaki Hanaki4, Koichiro Atsuda2 & Katsuya Otori1 The impact of overlapping risk factors on coronavirus disease (COVID-19) severity is unclear. To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity, we conducted a cohort study with 28,095 anonymized COVID-19 patients using data from the COVID-19 Research Database from January 1, 2020 to November 30, 2020. The mean age was 50.8 ± 17.5 years, and 11,802 (42%) patients were male. Data on age, race, sex, T2D complications, antidiabetic medication prescription, and body mass index ≥ 30 kg/m2 (obesity) were analysed using Cox proportional hazard models, with hospitalization risk and critical care within 30 days of COVID-19 diagnosis as the main outcomes. The risk scores were 0–4 for age ≥ 65 years, male sex, T2D, and obesity. Among the participants, 11,294 (61.9%) had obesity, and 4445 (15.8%) had T2D. T2D, obesity, and male sex were significantly associated with COVID-19 hospitalization risk. Regarding hospitalization risk scores, compared with those for hospitalization risk score 0 and critical care risk score 0, hazard ratios [95% confidence intervals] were 19.034 [10.470–34.600] and 55.803 [12.761–244.015] (P < 0.001) (P < 0.001), respectively, for risk score 4. Complications from diabetes and obesity increased hospitalization and critical care risks for COVID-19 patients. Coronavirus disease (COVID-19) is currently one of the most concerning infections ­globally1. It has a high incidence and mortality rate in the United ­States2. The risk of increasing COVID-19 severity has been reported, with men having a 2.76-fold higher risk of hospitalization owing to COVID-19 than women. According to Grasselli et al.3, 82% of patients admitted to intensive care units (ICUs) were men. Obesity was reported to increase the risk of COVID-19, ICU admission, and death by 1.46-, 2.13-, and 1.74-fold, respectively, suggesting that obesity may affect lung function and immune ­function4. Furthermore, the greatest risk of severe COVID-19 is ­age1. Additionally, statistical analyses by the Center for Disease Control reported an increase in COVID-19 risk with an increase in age; compared with the 18–29-year-old group, the 85-year-old group had a 13- and 630-fold increase in hospitalization and mortality risks, respectively. Therefore, patient characteristics, such as male sex, obesity, and advanced age, can be risk factors for severe d ­ isease5. Studies reported that COVID-19 comorbidities, including hypertension, chronic heart disease, lung d ­ isease6, and type 2 diabetes (T2D), remarkably affected disease ­severity7. T2D is a serious social problem in the United ­States8 because the number of newly diagnosed patients with T2D increased by 75% for all age groups between 1988 and 2­ 0109. Moreover, less than half of all American adults do not follow the recommended guidelines for diabetes ­care10, and obese men aged > 60 years are more likely to develop ­T2D11,12. Therefore, risk factors for T2D are considered similar to those for severe COVID-19. Although several reports exist on the risk of severe COVID-19, studies on severe COVID-19 owing to overlapping risk 1 Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, Kitasato University School of Pharmacy,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit